All Stories

  1. Newly diagnosed eosinophilic granulomatosis with polyangiitis in patients on biologics for severe asthma: A multicenter case series

    Article • The Journal of Allergy and Clinical Immunology In Practice, July 2025, Elsevier

    Dr Valentyna Yasinska

  2. High‐Dimensional Analysis of Type 2 Lymphocyte Dynamics During Mepolizumab or Dupilumab Treatment in Severe Asthma

    Article • Allergy, June 2025, Wiley

    Dr Valentyna Yasinska

  3. Targeting of the IL-5 pathway in severe asthma reduces mast cell progenitors

    Article • Journal of Allergy and Clinical Immunology, April 2025, Elsevier

    Dr Valentyna Yasinska

  4. Use of high-dose inhaled corticosteroids and risk of corticosteroid related adverse events in asthma -findings from the NORDSTAR cohort

    Article • The Journal of Allergy and Clinical Immunology In Practice, February 2025, Elsevier

    Dr Valentyna Yasinska

  5. Patient-centred composite scores as tools for assessment of response to biological therapy for paediatric and adult severe asthma

    Article • European Respiratory Journal, November 2024, European Respiratory Society (ERS)

    Alexander Mathioudakis, Dr Valentyna Yasinska

  6. Radiomultiomics: quantitative CT clusters of severe asthma associated with multiomics

    Article • European Respiratory Journal, October 2024, European Respiratory Society (ERS)

    Lars I. Andersson, Dr Massimo Caruso, Dr Valentyna Yasinska

  7. Characteristics of never-, switching, and persisting users of biologics for severe asthma – a SHARP-CRC study

    Article • September 2024, European Respiratory Society (ERS)

    Dr Valentyna Yasinska

  8. Characteristics of severe asthma patients requiring ICU treatment across the SHARP CRC

    Article • September 2024, European Respiratory Society (ERS)

    Dr Valentyna Yasinska

  9. Clinical characteristics of severe asthma patients in Europe, according to the percentage of GDP spent on healthcare- a SHARP-CRC study

    Article • September 2024, European Respiratory Society (ERS)

    Dr Valentyna Yasinska

  10. Dose-dependent association between inhaled corticosteroids and risk of corticosteroid related adverse events in asthma

    Article • September 2024, European Respiratory Society (ERS)

    Dr Valentyna Yasinska

  11. Health-related quality of life (HRQoL) in depression defined by clinicians and patients in severe asthma. Data from SHARP CRC

    Article • September 2024, European Respiratory Society (ERS)

    Dr Valentyna Yasinska

  12. Health-related quality of life and asthma control in patients receiving or not receiving biologic treatments for severe asthma. Data from SHARP CRC

    Article • September 2024, European Respiratory Society (ERS)

    Dr Valentyna Yasinska

  13. High-dose inhaled corticosteroid use associated with increased cardiovascular risk in patients with asthma

    Article • September 2024, European Respiratory Society (ERS)

    Dr Valentyna Yasinska

  14. Initial data analysis of the SHARP CRC patient population reveals a large heterogeneity among European patients with severe asthma

    Article • September 2024, European Respiratory Society (ERS)

    Dr Valentyna Yasinska

  15. Multimorbidity burden in severe asthma across the SHARP CRC

    Article • September 2024, European Respiratory Society (ERS)

    Dr Valentyna Yasinska

  16. Phospholipid composition of the respiratory tract lining fluid (RTLF) in subjects with Asthma and COPD

    Article • September 2024, European Respiratory Society (ERS)

    Dr Valentyna Yasinska

  17. Recurrent respiratory infections and allergy hallmarks at-risk progression to severe asthma

    Article • September 2024, European Respiratory Society (ERS)

    Dr Valentyna Yasinska

  18. Relationship between the Severe Asthma Questionnaire and the EQ-5D-5L for health-related quality of life in the SHARP CRC registry

    Article • September 2024, European Respiratory Society (ERS)

    Dr Valentyna Yasinska

  19. Severe Asthma Multimorbidity Clusters Across Europe; Findings From SHARP

    Article • September 2024, European Respiratory Society (ERS)

    Dr Valentyna Yasinska

  20. A modified COMSA score is a good tool to identify responders and non-responders to mepolizumab in severe asthma

    Article • September 2023, European Respiratory Society (ERS)

    Dr Valentyna Yasinska

  21. Late Breaking Abstract - Dynamics of the blood innate lymphoid cell compartment in patients with severe asthma undergoing type 2 biologics treatment: Initial findings in the BIOCROSS study

    Article • September 2023, European Respiratory Society (ERS)

    Dr Valentyna Yasinska

  22. Severe asthma trajectories in adults: findings from the NORDSTAR cohort

    Article • European Respiratory Journal, August 2023, European Respiratory Society (ERS)

    Dr Valentyna Yasinska

  23. Low levels of endogenous anabolic androgenic steroids in females with severe asthma taking corticosteroids

    Article • ERJ Open Research, August 2023, European Respiratory Society (ERS)

    Lars I. Andersson, Dr Valentyna Yasinska, Dr Massimo Caruso

  24. Prevalence and management of severe asthma in the Nordic countries: findings from the NORDSTAR cohort

    Article • ERJ Open Research, February 2023, European Respiratory Society (ERS)

    Dr Valentyna Yasinska

  25. Definitions of non-response and response to biological therapy for severe asthma: a systematic review

    Article • ERJ Open Research, January 2023, European Respiratory Society (ERS)

    Dr Valentyna Yasinska

  26. Development of Core Outcome Measures sets for paediatric and adult Severe Asthma (COMSA)

    Article • European Respiratory Journal, October 2022, European Respiratory Society (ERS)

    Dr Valentyna Yasinska

  27. The prevalence of severe asthma, use of oral corticosteroid and management strategies in the Nordic countries: results from the pan-Nordic NORDSTAR cohort

    Article • September 2022, European Respiratory Society (ERS)

    Dr Valentyna Yasinska

  28. Suppressive effect of corticosteroid treatment on urinary levels of androgens and cortisol in mild and severe asthma

    Article • September 2022, European Respiratory Society (ERS)

    Dr Valentyna Yasinska

  29. The effect of the COVID-19 pandemic on severe asthma care in Europe - will care change for good?

    Article • ERJ Open Research, April 2022, European Respiratory Society (ERS)

    Katrien Eger, Dr Valentyna Yasinska

  30. Eosinophilic airway diseases: basic science, clinical manifestations and future challenges

    Article • European Clinical Respiratory Journal, March 2022, Taylor & Francis

    Dr Valentyna Yasinska

  31. Mepolizumab decreases urinary excretion of LTE4 in severe asthma

    Article • September 2020, European Respiratory Society (ERS)

    Dr Valentyna Yasinska

  32. NORDSTAR – Paving the way for a new era in asthma research

    Article • European Respiratory Journal, March 2020, European Respiratory Society (ERS)

    Kirk Geale, Dr Valentyna Yasinska

  33. Severe asthma in different European registries

    Article • European Respiratory Journal, October 2019, European Respiratory Society (ERS)

    Job J.M.H. van Bragt, Dr Valentyna Yasinska

  34. Characteristics and treatment regimens across ERS SHARP severe asthma registries

    Article • September 2019, European Respiratory Society (ERS)

    Dr Valentyna Yasinska